GlaxoSmithKline submits UMEC/VI for approval in EU

9th Jan 2013 12:40

Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD). The companies previously announced the submission of a regulatory application in the US on December 18th. The firms also plan to make submissions for regulatory approval for UMEC monotherapy later this year. Glaxo's share price rose 0.44% to 1,379.50p by 13:22.NR

Top Risers

Share	Price	Change
Huddled Group (HUD)	0.85	24.14%
Eurasia Mining (EUA)	2.80	19.15%
Genincode (GENI)	0.725	16%
Medpal AI (MPAL)	5.25	14.13%
Light Science Technologies (LST)	0.875	12.9%

Top Fallers

Share	Price	Change
Catenai Plc (CTAI)	0.0575	-39.47%
Petra Diamonds (PDL)	2.60	-26.14%
Focus Xplore (FOX)	0.019	-22.45%
Litigation Cap. (LIT)	0.301	-20.12%
Abrdn Property (API)	1.52	-15.56%

Top By Volume

Share	Price	Volume
Ethernity Net (ENET)	0.0019	1,922,336,250
Forgent (FORG)	0.0115	591,087,829
Premier African Minerals (PREM)	0.0044	313,776,718
Focus Xplore (FOX)	0.019	253,421,870
Bezant Resources PLC (BZT)	0.11	246,929,868

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.